Breaking News Bar

Business News and Information

Amgen challenge to Genentech $6 billion cancer drug OK'd by FDA

Avastin is South San Francisco-based Genentech's best-selling cancer drug — and the second-biggest cancer drug worldwide. Now Amgen will eat into some of those sales.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
bottom clear